JP2023534916A5 - - Google Patents

Info

Publication number
JP2023534916A5
JP2023534916A5 JP2022581408A JP2022581408A JP2023534916A5 JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5 JP 2022581408 A JP2022581408 A JP 2022581408A JP 2022581408 A JP2022581408 A JP 2022581408A JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
subject
administration
nmosd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039911 external-priority patent/WO2022006283A2/en
Publication of JP2023534916A publication Critical patent/JP2023534916A/ja
Publication of JP2023534916A5 publication Critical patent/JP2023534916A5/ja
Pending legal-status Critical Current

Links

JP2022581408A 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法 Pending JP2023534916A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US63/046,133 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US63/052,093 2020-07-15
US202063071092P 2020-08-27 2020-08-27
US63/071,092 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (2)

Publication Number Publication Date
JP2023534916A JP2023534916A (ja) 2023-08-15
JP2023534916A5 true JP2023534916A5 (cg-RX-API-DMAC7.html) 2024-07-09

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581408A Pending JP2023534916A (ja) 2020-06-30 2021-06-30 視神経脊髄炎スペクトラム障害を治療する方法

Country Status (11)

Country Link
US (1) US20230406928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172211A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534916A (cg-RX-API-DMAC7.html)
KR (1) KR20230030642A (cg-RX-API-DMAC7.html)
CN (1) CN116234571A (cg-RX-API-DMAC7.html)
AU (1) AU2021299307A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178954A1 (cg-RX-API-DMAC7.html)
IL (1) IL299381A (cg-RX-API-DMAC7.html)
MX (1) MX2022016236A (cg-RX-API-DMAC7.html)
WO (1) WO2022006283A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977843B1 (ko) * 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药(烟台)有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用

Similar Documents

Publication Publication Date Title
Yang et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder
DK2493503T3 (en) DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody
JP7125932B2 (ja) 凝固第ix因子および/または活性化凝固第ix因子ならびに凝固第x因子および/または活性化凝固第x因子を認識する二重特異性抗体の使用法
US9458241B2 (en) Antibody induced cell membrane wounding
EP3747464B1 (en) Methods for treating progressive multiple sclerosis using an anti-cd20 antibody
D'Amico et al. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives
JP2022033868A5 (cg-RX-API-DMAC7.html)
JP7541505B2 (ja) アルツハイマー病の治療及び予防方法
JP2024112859A5 (cg-RX-API-DMAC7.html)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2018523684A5 (cg-RX-API-DMAC7.html)
JP2021532126A5 (cg-RX-API-DMAC7.html)
JP2022121658A (ja) アミロイドーシスを処置するための組成物
WO2013171289A1 (en) Combination of cd37 antibodies with further agents
WO2018015880A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2025514142A5 (cg-RX-API-DMAC7.html)
WO2007035857A2 (en) Treatment of b cell diseases using anti-germline antibody binding agents
JP2021529766A5 (cg-RX-API-DMAC7.html)
JP2020500161A5 (cg-RX-API-DMAC7.html)
EP4583852A1 (en) Combination treatment of scyllo-inositol and vitamin d and/or other vitamins or active ingredients to treat cognitive disorders
JP2023510854A5 (cg-RX-API-DMAC7.html)
JP2024532438A5 (cg-RX-API-DMAC7.html)
JP2023531722A5 (cg-RX-API-DMAC7.html)
CA3158364A1 (en) Anti-alpha-synuclein monoclonal antibodies, and methods using same
JP2024522620A5 (cg-RX-API-DMAC7.html)